Yes, Aranesp Is an Injection
Aranesp (darbepoetin alfa) is administered by injection, either subcutaneously (under the skin) or intravenously (into a vein), depending on the treatment setting.[1] It's a recombinant erythropoiesis-stimulating agent used to treat anemia in patients with chronic kidney disease or chemotherapy-induced anemia.
How Is Aranesp Typically Given?
Dosing occurs 1-3 times per week or less frequently (every 2-4 weeks) based on patient needs and response. Prefilled syringes (10 mcg to 500 mcg strengths) or vials allow self-injection at home after training, or administration in clinics/hospitals.[1][2] Subcutaneous use is common for home settings; IV for dialysis patients.
What Happens If You Miss a Dose?
Consult a doctor immediately—do not double up. Restart at the next scheduled dose to avoid overdose risks like blood clots or high hemoglobin levels.[1]
Why Injection Instead of Pills?
Aranesp mimics the hormone erythropoietin to boost red blood cell production, requiring direct bloodstream delivery for efficacy. Oral forms aren't available due to poor absorption and stability issues with protein-based biologics like this.[2]
Common Side Effects Patients Report
Injection-site reactions (pain, redness), hypertension, and vascular access issues top lists. Serious risks include pure red cell aplasia (rare immune reaction) and increased stroke/heart attack odds in some groups.[1][3]
Who Makes Aranesp and What's the Cost?
Amgen manufactures it. List prices range $300-$1,500 per syringe (varies by dose/quantity), though insurance/copay assistance often lowers patient costs.[2]
When Does Aranesp's Patent Expire?
Key U.S. patents expired around 2024, opening doors for biosimilars like those from Pfizer and others, potentially cutting prices.4
[1]: Aranesp Prescribing Information, Amgen (aranesp.com)
[2]: Drugs.com/Aranesp
[3]: FDA Label, DailyMed